vs
BIODESIX INC（BDSX）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
BIODESIX INC的季度营收约是REDWOOD TRUST INC的1.1倍（$28.8M vs $25.9M），REDWOOD TRUST INC净利率更高（77.2% vs -13.8%，领先91.1%），BIODESIX INC同比增速更快（40.8% vs -6.1%），过去两年BIODESIX INC的营收复合增速更高（39.3% vs -41.0%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
BDSX vs RWT — 直观对比
营收规模更大
BDSX
是对方的1.1倍
$25.9M
营收增速更快
BDSX
高出46.8%
-6.1%
净利率更高
RWT
高出91.1%
-13.8%
两年增速更快
BDSX
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $25.9M |
| 净利润 | $-4.0M | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | — |
| 净利率 | -13.8% | 77.2% |
| 营收同比 | 40.8% | -6.1% |
| 净利润同比 | 51.8% | 402.6% |
| 每股收益（稀释后） | $-3.35 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXRWT
| Q4 25 | $28.8M | $25.9M | ||
| Q3 25 | $21.8M | $15.0M | ||
| Q2 25 | $20.0M | $13.8M | ||
| Q1 25 | $18.0M | $27.9M | ||
| Q4 24 | $20.4M | $27.6M | ||
| Q3 24 | $18.2M | $25.5M | ||
| Q2 24 | $17.9M | $67.4M | ||
| Q1 24 | $14.8M | $74.5M |
净利润BDSXRWT
| Q4 25 | $-4.0M | $20.0M | ||
| Q3 25 | $-8.7M | $-7.7M | ||
| Q2 25 | $-11.5M | $-98.5M | ||
| Q1 25 | $-11.1M | $16.1M | ||
| Q4 24 | $-8.3M | $-6.6M | ||
| Q3 24 | $-10.3M | $14.8M | ||
| Q2 24 | $-10.8M | $15.5M | ||
| Q1 24 | $-13.6M | $30.3M |
营业利润率BDSXRWT
| Q4 25 | -6.8% | — | ||
| Q3 25 | -32.4% | -9.0% | ||
| Q2 25 | -48.6% | -679.0% | ||
| Q1 25 | -50.9% | 80.2% | ||
| Q4 24 | -32.5% | -1.3% | ||
| Q3 24 | -47.3% | 86.1% | ||
| Q2 24 | -46.0% | 30.3% | ||
| Q1 24 | -74.4% | 41.3% |
净利率BDSXRWT
| Q4 25 | -13.8% | 77.2% | ||
| Q3 25 | -40.0% | -51.4% | ||
| Q2 25 | -57.3% | -712.0% | ||
| Q1 25 | -61.8% | 57.8% | ||
| Q4 24 | -40.4% | -24.0% | ||
| Q3 24 | -56.5% | 58.1% | ||
| Q2 24 | -60.3% | 23.0% | ||
| Q1 24 | -91.9% | 40.6% |
每股收益（稀释后）BDSXRWT
| Q4 25 | $-3.35 | $0.11 | ||
| Q3 25 | $-1.16 | $-0.08 | ||
| Q2 25 | $-0.08 | $-0.76 | ||
| Q1 25 | $-0.08 | $0.10 | ||
| Q4 24 | $-5.02 | $-0.08 | ||
| Q3 24 | $-1.40 | $0.09 | ||
| Q2 24 | $-0.08 | $0.10 | ||
| Q1 24 | $-0.14 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $255.7M |
| 总债务越低越好 | $50.0M | — |
| 股东权益账面价值 | $-2.5M | $982.6M |
| 总资产 | $87.5M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXRWT
| Q4 25 | $19.0M | $255.7M | ||
| Q3 25 | $16.6M | $226.3M | ||
| Q2 25 | $20.7M | $302.0M | ||
| Q1 25 | $17.6M | $259.9M | ||
| Q4 24 | $26.2M | $245.2M | ||
| Q3 24 | $31.4M | $253.7M | ||
| Q2 24 | $42.2M | $275.6M | ||
| Q1 24 | $11.5M | $275.4M |
总债务BDSXRWT
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | $1.7B |
股东权益BDSXRWT
| Q4 25 | $-2.5M | $982.6M | ||
| Q3 25 | $-1.7M | $999.0M | ||
| Q2 25 | $1.1M | $1.1B | ||
| Q1 25 | $11.1M | $1.2B | ||
| Q4 24 | $20.9M | $1.2B | ||
| Q3 24 | $27.9M | $1.2B | ||
| Q2 24 | $36.3M | $1.2B | ||
| Q1 24 | $-5.5M | $1.2B |
总资产BDSXRWT
| Q4 25 | $87.5M | $23.7B | ||
| Q3 25 | $88.7M | $22.6B | ||
| Q2 25 | $87.7M | $21.3B | ||
| Q1 25 | $86.2M | $19.9B | ||
| Q4 24 | $97.2M | $18.3B | ||
| Q3 24 | $102.7M | $18.4B | ||
| Q2 24 | $115.8M | $16.5B | ||
| Q1 24 | $87.2M | $15.1B |
负债/权益比BDSXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $692.0K | — |
| 自由现金流率自由现金流/营收 | 2.4% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $-23.5M | — |
8季度趋势，按日历期对齐
经营现金流BDSXRWT
| Q4 25 | $778.0K | $-10.1B | ||
| Q3 25 | $-8.9M | $-2.7B | ||
| Q2 25 | $-6.6M | $-2.1B | ||
| Q1 25 | $-8.6M | $-2.0B | ||
| Q4 24 | $-4.1M | $-5.9B | ||
| Q3 24 | $-10.7M | $-2.1B | ||
| Q2 24 | $-18.6M | $-2.0B | ||
| Q1 24 | $-15.3M | $-954.2M |
自由现金流BDSXRWT
| Q4 25 | $692.0K | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-8.7M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-10.9M | — | ||
| Q2 24 | $-20.5M | — | ||
| Q1 24 | $-15.5M | — |
自由现金流率BDSXRWT
| Q4 25 | 2.4% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -33.1% | — | ||
| Q1 25 | -48.3% | — | ||
| Q4 24 | -24.2% | — | ||
| Q3 24 | -60.1% | — | ||
| Q2 24 | -114.3% | — | ||
| Q1 24 | -104.9% | — |
资本支出强度BDSXRWT
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率BDSXRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
RWT
暂无分部数据
